📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: EngMab

1.1 - Company Overview

EngMab Logo

EngMab

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biotechnology as an independent company funded by private Swiss investors.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to EngMab

Arcellx Logo

Arcellx

HQ: United States Website
  • Description: Provider of immune cell therapies, including anitocabtagene autoleucel, a CAR-T targeting BCMA for relapsed or refractory multiple myeloma (Phase 1); ACLX-001, a controllable ARC-T cell therapy with a bivalent SparX protein targeting BCMA for relapsed or refractory multiple myeloma; and ACLX-002, an ARC-SparX therapy targeting CD123 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arcellx company profile →
Trellis Bioscience Logo

Trellis Bioscience

HQ: United States Website
  • Description: Provider of therapeutic antibody therapies for infectious diseases and oncology, developing TRL1068 to disrupt bacterial biofilms and enhance antibiotics in prosthetic joint infections, TRL404 pan-influenza antibody cocktail, TRL3D3 targeting RSV, and TRL345 against cytomegalovirus, enabled by the CellSpot platform to discover high-affinity monoclonal antibodies from human memory B-cells.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Trellis Bioscience company profile →
ImmunoGenesis Logo

ImmunoGenesis

HQ: United States Website
  • Description: Provider of immune therapies for tumor treatment, including IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor with cytotoxic effector function for immune-excluded tumors resistant to immunotherapies; IMGS-501, an antibody-conjugated STING agonist delivered via PD-L1/PD-L2 targeting to tumor sites; and IMGS-101, a hypoxia-reversal agent that reoxygenates the tumor microenvironment to enable T-cell access.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ImmunoGenesis company profile →
Vitaeris Logo

Vitaeris

HQ: Canada Website
  • Description: Provider of clinical-stage biopharmaceutical development by a Canadian company focused on the anti-interleukin-6 monoclonal antibody Clazakizumab, with global exclusive rights licensed from Alder Biopharmaceuticals, pursuing applications in chronic inflammatory diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vitaeris company profile →
Intercell Logo

Intercell

HQ: Austria Website
  • Description: Provider of vaccine design and development for prevention and treatment of infectious diseases, leveraging proprietary technology platforms to discover and develop antigens and adjuvants. Founded in 1998 and headquartered in Vienna, Austria.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Intercell company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for EngMab

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to EngMab

2.2 - Growth funds investing in similar companies to EngMab

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for EngMab

4.2 - Public trading comparable groups for EngMab

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to EngMab

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About EngMab

What does EngMab do?

EngMab is a provider of biotechnology as an independent company funded by private Swiss investors.

Who are EngMab's competitors?

EngMab's competitors and similar companies include Arcellx, Trellis Bioscience, ImmunoGenesis, Vitaeris, and Intercell.

Where is EngMab headquartered?

EngMab is headquartered in United States.

How many employees does EngMab have?

EngMab has 1,000 employees 🔒.

When was EngMab founded?

EngMab was founded in 2010 🔒.

What sector and industry vertical is EngMab in?

EngMab is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for EngMab

Who are the top strategic acquirers in EngMab's sector and industry

Top strategic M&A buyers and acquirers in EngMab's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for EngMab?

Top strategic M&A buyers groups and sectors for EngMab include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in EngMab's sector and industry vertical

Which are the top PE firms investing in EngMab's sector and industry vertical?

Top PE firms investing in EngMab's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in EngMab's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in EngMab's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in EngMab's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to EngMab include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in EngMab's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for EngMab?

The key public trading comparables and valuation benchmarks for EngMab include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for EngMab for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for EngMab with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in EngMab's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for EngMab with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in EngMab's' sector and industry vertical?

Access recent funding rounds and capital raises in EngMab's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for EngMab